{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:52:13Z","timestamp":1794862333537,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12957-018-1535-y","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T13:11:24Z","timestamp":1545052284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Upregulation of the solute carrier family 7 genes is indicative of poor prognosis in papillary thyroid carcinoma"],"prefix":"10.1186","volume":"16","author":[{"given":"Lei","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongrui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingxian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunli","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,17]]},"reference":[{"issue":"1","key":"1535_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3322\/caac.21254","volume":"65","author":"R Siegel","year":"2015","unstructured":"Siegel R, Miller K, Jemal A. Cancer statistics , 2015. CA Cancer J Clin. 2015;65(1):29.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1535_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/0003489414523563","volume":"123","author":"SL Oyer","year":"2014","unstructured":"Oyer SL, Fritsch VA, Lentsch EJ. Comparison of survival rates between papillary and follicular thyroid carcinomas among 36,725 patients. Ann Otol Rhinol Laryngol. 2014;123(2):94\u2013100.","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"2","key":"1535_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00232-006-0875-7","volume":"213","author":"EI Closs","year":"2006","unstructured":"Closs EI, Boissel JP, Habermeier A, Rotmann A. Structure and function of cationic amino acid transporters (CATs). J Membr Biol. 2006;213(2):67\u201377.","journal-title":"J Membr Biol"},{"issue":"9","key":"1535_CR4","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1158\/0008-5472.CAN-14-3745","volume":"75","author":"YD Bhutia","year":"2015","unstructured":"Bhutia YD, Babu E, Ramachandran S, Ganapathy V. Amino acid transporters in cancer and their relevance to \u201cglutamine addiction\u201d: novel targets for the design of a new class of anticancer drugs. Cancer Res. 2015;75(9):1782\u20138.","journal-title":"Cancer Res"},{"issue":"12","key":"1535_CR5","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1111\/j.1349-7006.2008.00969.x","volume":"99","author":"K Kaira","year":"2008","unstructured":"Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, et al. L-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci. 2008;99(12):2380\u20136.","journal-title":"Cancer Sci"},{"issue":"5","key":"1535_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.molcel.2012.09.017","volume":"48","author":"A Elorza","year":"2012","unstructured":"Elorza A, Soro-Arn\u00e1iz I, Mel\u00e9ndez-Rodr\u00edguez F, Rodr\u00edguez-Vaello V, Marsboom G, de C\u00e1rcer G, et al. HIF2\u03b1 acts as an mTORC1 activator through the amino acid carrier SLC7A5. Mol Cell. 2012;48(5):681\u201391.","journal-title":"Mol Cell"},{"issue":"7239","key":"1535_CR7","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nature07823","volume":"458","author":"P Gao","year":"2009","unstructured":"Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. C-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458(7239):762\u20135.","journal-title":"Nature"},{"issue":"5","key":"1535_CR8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1089\/ars.2011.4391","volume":"18","author":"J Lewerenz","year":"2013","unstructured":"Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, et al. The cystine\/glutamate antiporter system x c \u2212 in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal. 2013;18(5):522\u201355.","journal-title":"Antioxid Redox Signal"},{"issue":"3","key":"1535_CR9","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"TCGAR Network","year":"2014","unstructured":"Network TCGAR, Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676\u201390.","journal-title":"Cell"},{"issue":"12","key":"1535_CR10","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1210\/jc.2012-1775","volume":"97","author":"R Elisei","year":"2012","unstructured":"Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, et al. The BRAFV600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012;97(12):4390\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1535_CR11","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.surg.2012.08.039","volume":"152","author":"JD Prescott","year":"2012","unstructured":"Prescott JD, Sadow PM, Hodin RA, Le LP, Gaz RD, Randolph GW, et al. BRAF(V600E) status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery. 2012;152(6):984\u201390.","journal-title":"Surgery"},{"issue":"1","key":"1535_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/modpathol.2012.152","volume":"26","author":"RK Virk","year":"2013","unstructured":"Virk RK, Van Dyke AL, Finkelstein A, Prasad A, Gibson J, Hui P, et al. BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype\u2013phenotype correlation. Mod Pathol. 2013;26(1):62\u201370.","journal-title":"Mod Pathol"},{"issue":"12","key":"1535_CR13","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1210\/jc.2009-1233","volume":"94","author":"M Volante","year":"2009","unstructured":"Volante M, Rapa I, Gandhi M, Bussolati G, Giachino D, Papotti M, et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab. 2009;94(12):4735\u201341.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1535_CR14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1089\/thy.2011.0261","volume":"22","author":"M Fukahori","year":"2012","unstructured":"Fukahori M, Yoshida A, Hayashi H, Yoshihara M, Matsukuma S, Sakuma Y, et al. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. Thyroid. 2012;22(7):683\u20139.","journal-title":"Thyroid"},{"key":"1535_CR15","doi-asserted-by":"crossref","unstructured":"Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000. ISBN 0-387-98784-3.","DOI":"10.1007\/978-1-4757-3294-8"},{"issue":"June","key":"1535_CR16","first-page":"1","volume":"2008","author":"J Fox","year":"2002","unstructured":"Fox J. Cox proportional-hazards regression for survival data the cox proportional-hazards model. Most. 2002;2008(June):1\u201318.","journal-title":"Most"},{"issue":"41","key":"1535_CR17","doi-asserted-by":"publisher","first-page":"12387","DOI":"10.1021\/bi011345c","volume":"40","author":"N V\u00e9kony","year":"2001","unstructured":"V\u00e9kony N, Wolf S, Boissel JP, Gnauert K, Closs EI. Human cationic amino acid transporter hCAT-3 is preferentially expressed in peripheral tissues. Biochemistry. 2001;40(41):12387\u201394.","journal-title":"Biochemistry"},{"issue":"2","key":"1535_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0005-2736(01)00384-4","volume":"1514","author":"O Yanagida","year":"2001","unstructured":"Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta - Biomembr. 2001;1514(2):291\u2013302.","journal-title":"Biochim Biophys Acta - Biomembr"},{"issue":"1","key":"1535_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1440-1827.2008.02319.x","volume":"59","author":"T Sakata","year":"2009","unstructured":"Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T, et al. L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int. 2009;59(1):7\u201318.","journal-title":"Pathol Int"},{"issue":"4","key":"1535_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/jso.20257","volume":"90","author":"H Kobayashi","year":"2005","unstructured":"Kobayashi H, Ishii Y, Takayama T. Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol. 2005;90(4):233\u20138.","journal-title":"J Surg Oncol"},{"issue":"5","key":"1535_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1440-1827.2011.02650.x","volume":"61","author":"M Ichinoe","year":"2011","unstructured":"Ichinoe M, Mikami T, Yoshida T, Igawa I, Tsuruta T, Nakada N, et al. High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Pathol Int. 2011;61(5):281\u20139.","journal-title":"Pathol Int"},{"issue":"11","key":"1535_CR22","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/jclinpath-2012-200826","volume":"65","author":"N Yanagisawa","year":"2012","unstructured":"Yanagisawa N, Ichinoe M, Mikami T, Nakada N, Hana K, Koizumi W, et al. High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas. J Clin Pathol. 2012;65(11):1019\u201323.","journal-title":"J Clin Pathol"},{"key":"1535_CR23","doi-asserted-by":"crossref","unstructured":"Kobayashi T, Yan H, Kurahashi Y, Ito Y, Maeda H, Tada T. Role of GalNAc4S-6ST in Astrocytic Tumor Progression. PLoS One. 2013;8(1):1\u20139.","DOI":"10.1371\/journal.pone.0054278"},{"issue":"4","key":"1535_CR24","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/bjc.2012.310","volume":"107","author":"K Kaira","year":"2012","unstructured":"Kaira K, Sunose Y, Arakawa K, Ogawa T, Sunaga N, Shimizu K, et al. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer. 2012;107(4):632\u20138.","journal-title":"Br J Cancer"},{"key":"1535_CR25","doi-asserted-by":"crossref","unstructured":"Shimizu A, Kaira K, Kato M, Yasuda M, Takahashi A, Tominaga H, et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma. Melanoma Res. 2015;25(5).","DOI":"10.1097\/CMR.0000000000000181"},{"issue":"5","key":"1535_CR26","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/cam4.272","volume":"3","author":"N Yanagisawa","year":"2014","unstructured":"Yanagisawa N, Hana K, Nakada N, Ichinoe M, Koizumi W, Endou H, et al. High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas. Cancer Med. 2014;3(5):1246\u201355.","journal-title":"Cancer Med"},{"key":"1535_CR27","doi-asserted-by":"crossref","unstructured":"Betsunoh H, Fukuda T, Anzai N, Nishihara D, Mizuno T, Yuki H, et al. Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma. BMC Cancer. 2013;13.","DOI":"10.1186\/1471-2407-13-509"},{"issue":"17","key":"1535_CR28","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1089\/scd.2017.0123","volume":"26","author":"MD Polewski","year":"2017","unstructured":"Polewski MD, Reveron-Thornton RF, Cherryholmes GA, Marinov GK, Aboody KS. SLC7A11 overexpression in glioblastoma is associated with increased cancer stem cell-like properties. Stem Cells Dev. 2017;26(17):1236\u201346.","journal-title":"Stem Cells Dev"},{"issue":"289","key":"1535_CR29","doi-asserted-by":"publisher","first-page":"289ra86","DOI":"10.1126\/scitranslmed.aaa8103","volume":"7","author":"SM Robert","year":"2015","unstructured":"Robert SM, Buckingham SC, Campbell SL, Robel S, Holt KT, Ogunrinu-Babarinde T, et al. SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. Sci Transl Med. 2015;7(289):289ra86.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1535_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1227\/NEU.0b013e318276b2de","volume":"72","author":"S Takeuchi","year":"2013","unstructured":"Takeuchi S, Wada K, Toyooka T, Shinomiya N, Shimazaki H, Nakanishi K, et al. Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas. Neurosurgery. 2013;72(1):33\u201341.","journal-title":"Neurosurgery"},{"issue":"12","key":"1535_CR31","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1158\/1541-7786.MCR-16-0028","volume":"14","author":"MD Polewski","year":"2016","unstructured":"Polewski MD, Reveron-Thornton RF, Cherryholmes GA, Marinov GK, Cassady K, Aboody KS. Increased expression of system xc- in glioblastoma confers an altered metabolic state and temozolomide resistance. Mol Cancer Res. 2016;14(12):1229\u201342.","journal-title":"Mol Cancer Res"},{"issue":"4","key":"1535_CR32","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccr.2013.08.020","volume":"24","author":"LA Timmerman","year":"2013","unstructured":"Timmerman LA, Holton T, Yuneva M, Louie RJ, Padr\u00f3 M, Daemen A, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013;24(4):450\u201365.","journal-title":"Cancer Cell"},{"key":"1535_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2017.01.002","volume":"104","author":"JL Roh","year":"2017","unstructured":"Roh JL, Kim EH, Jang H, Shin D. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition. Free Radic Biol Med. 2017;104:1\u20139.","journal-title":"Free Radic Biol Med"},{"key":"1535_CR34","doi-asserted-by":"crossref","unstructured":"Yoon BR, Oh YJ, Kang SW, Lee EB, Lee WW. Role of SLC7A5 in metabolic reprogramming of human monocyte\/macrophage immune responses. Front Immunol. 2018;9:53.","DOI":"10.3389\/fimmu.2018.00053"},{"issue":"10","key":"1535_CR35","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.tibs.2018.05.003","volume":"43","author":"P Kandasamy","year":"2018","unstructured":"Kandasamy P, Gyimesi G, Kanai Y, Hediger MA. Amino acid transporters revisited: new views in health and disease. Trends Biochem Sci. 2018;43(10):752\u201389.","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"1535_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-017-0753-1","volume":"17","author":"GE Naoum","year":"2018","unstructured":"Naoum GE, Morkos M, Kim B, Arafat W. Novel targeted therapies and immunotherapy for advanced thyroid cancers. Mol Cancer Mol Cancer. 2018;17(1):1\u201315.","journal-title":"Mol Cancer Mol Cancer"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-018-1535-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12957-018-1535-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-018-1535-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:13:05Z","timestamp":1576541585000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-018-1535-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1535"],"URL":"https:\/\/doi.org\/10.1186\/s12957-018-1535-y","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"27 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"235"}}